evaluation of amg 420, an anti-bcma bispecific t-cell engager (bite) immunotherapy in patients w...
Published 5 years ago • 367 plays • Length 7:13Download video MP4
Download video MP3
Similar videos
-
2:11
amg 420 and amg 701 in r/r myeloma
-
6:52
multiple myeloma: anti-bcma bite amg 701 shows preclinical promise
-
5:26
novel bispecific t-cell engager molecule shows promise in r/r multiple myeloma
-
5:38
amg 757: dll3 targeting, half-life extended bispecific t-cell engager immuno-oncology therapy, i...
-
5:27
amg 160: a psma-targeted, bispecific t-cell engager immune therapy for mcrpc
-
3:35
amg 330: an anti-cd33 bispecific t-cell engager antibody construct in relapsed/refractory aml
-
9:00
bispecific t-cell engaging therapy for adult all
-
7:12
dose escalation of regn1979 in patients with relapsed and refractory b-nhl
-
5:40
current concepts and future developments in t-cell-based immunotherapy of aml
-
4:16
updates from amg 330 in aml
-
34:53
engineered t cell with cars and tcrs for hematologic malignancy
-
1:38
update on amg 330 bispecific for r/r aml
-
2:48
ameli-01: safety and efficacy of ucart123v1.2 in r/r aml
-
7:11
testing the limits: the potential of car t-cell therapy
-
2:03
engineering multi-antigenic car t-cells for aml
-
2:45
modulation of amg 330-mediated t-cell proliferation and cytotoxicity
-
56:39
immunology fall 2019 lecture 24: peripheral b cell responses
-
0:47
anti-cd47 antibodies for complex karyotype aml
-
0:18
medical device package burst test astm f2054 at westpak inc.